|Synonyms||LP-1, pre-B cell factor|
|Molecular Weight||Approximately 17.4 kDa, a single non-glycosylated polypeptide chain containing 152 amino acids.|
|AA Sequence||DCDIEGKDGK QYESVLMVSI DQLLDSMKEI GSNCLNNEFN FFKRHICDAN KEGMFLFRAA RKLRQFLKMN STGDFDLHLL KVSEGTTILL NCTGQVKGRK PAALGEAQPT KSLEENKSLK EQKKLNDLCF LKRLLQEIKT CWNKILMGTK EH|
|Purity||> 98 % by SDS-PAGE and HPLC analyses.|
|Biological Activity||Assay #1:Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using murine 2E8 cells is less than 0.5 ng/ml, corresponding to a specific activity of > 2.0 × 106 IU/mg. Assay #2: Fully biologically active when compared to standard. The ED50 as determined by a cell proliferation assay using PHA-activated human peripheral blood lymphocytes (PBL) is 0.1-0.5 ng/mL. The specific activity of Recombinant Human IL-7 is approximately 2.0 × 108 units/mg, which is calibrated against human IL-7 WHO Standard (NIBSC code: 90/530).|
|Physical Appearance||Sterile Filtered White lyophilized (freeze-dried) powder.|
|Formulation||Lyophilized from a 0.2 µm filtered concentrated solution in PBS, pH 7.4.|
|Endotoxin||Less than 0.01 EU/µg of rHuIL-7 GMP as determined by LAL method.|
|Reconstitution||We recommend that this vial be briefly centrifuged prior to opening to bring the contents to the bottom. Reconstitute in sterile distilled water or aqueous buffer containing 0.1 % BSA to a concentration of 0.1-1.0 mg/mL. Stock solutions should be apportioned into working aliquots and stored at ≤ -20 °C. Further dilutions should be made in appropriate buffered solutions.|
|Stability & Storage||Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
A minimum of 12 months when stored at ≤ -20 °C as supplied. Refer to lot specific COA for the Use by Date.
1 month, 2 to 8 °C under sterile conditions after reconstitution.
3 months, -20 to -70 °C under sterile conditions after reconstitution.
|Usage||This GMP product can be for research use or further manufacturing use.|
|Quality statement||The manufacture and testing of this product is in compliance with ICH Q7a guidelines.|
|Reference||1. Goodwin RG, Lupton S, Schmierer A, et al. 1989. Proc Natl Acad Sci U S A. 86:302-6.|
2. Sutherland GR, Baker E, Fernandez KE, et al. 1989. Hum Genet. 82:371-2.
3. Lupton SD, Gimpel S, Jerzy R, et al. 1990. J Immunol. 144:3592-601.
4. Noguchi M, Nakamura Y, Russell SM, et al. 1993. Science. 262:1877-80.
5. Fry TJ, Mackall CL. 2002. Blood. 99:3892-904.
6. Fry TJ, Mackall CL. 2002. J Hematother Stem Cell Res. 11:803-7.
|Background||Interleukin-7 (IL-7) is encoded by the IL7 gene and secreted by stromal cells in the red marrow and thymus. It binds to the IL-7 receptor, a heterodimer consisting of IL-7 receptor alpha and IL-2 receptor gamma chain. IL-7 stimulates the differentiation of hematopoietic stem cells into lymphoid progenitor cells and also stimulates proliferation of B cells, T cells and NK cells. Murine IL-7 has approximately 65 % amino acid sequence identity with human IL-7 and both proteins exhibit cross-speciesactivity. IL-7 as an immunotherapy agent has been examinedin many human clinical trials for various malignancies and during HIV infection.|